Quantinuum (QNT): Wide Analyst Range Leaves Room for Debate on $95 Target

Key Takeaways

• The central price target of $95 represents the arithmetic mean of 11 verified analyst price targets, rounded from an average of roughly $94.50.
• With the latest verified close near $33.60, the stock would require an appreciation of about 183% to reach that level—a substantial move under any measure.
• Individual targets span from a low of $60 (Yorkville Ives) to a high of $155 (Rosenblatt Securities), underscoring significant disagreement on valuation.
• Positive elements include a record quantum error-correction achievement, an approximately $2.1 billion net cash position, and a hardware roadmap that extends through 2029.
• Key risks involve ongoing heavy losses, negative EPS, an extremely elevated price-to-sales ratio, and execution challenges on product timelines.

Understanding the Analyst Consensus

The $95 central target comes from 11 individually attributed forecasts that include the analyst name, firm, target, and date. The range stretches from $60 to $155, and the arithmetic mean of roughly $94.50 rounds neatly to $95. Other aggregators align closely, with MarketBeat showing an average near $94 and S&P Global data pointing to about $96.

Overall sentiment leans constructive, carrying a Strong Buy-style consensus and many targets clustered between $90 and $100 from firms such as Needham, Craig-Hallum, Evercore ISI, Cantor Fitzgerald, Mizuho, Jefferies, and Bank of America. Still, the spread remains unusually broad. Rosenblatt’s $155 target reflects strong conviction in Quantinuum’s trapped-ion approach, while Morgan Stanley’s Joseph Moore upgraded the name to Overweight and called it a top pick in October 2026 yet lowered his target from $78 to $62. One firm, Wall Street Zen, maintains a Sell rating. Analysts appear aligned on the technology’s long-term promise but differ markedly on how much of that promise is already reflected in the price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Valuation and the Path to the Target

At a recent close of $33.60, reaching $95 would require roughly 183% upside. The shares have already declined more than 30% in the past month and over 40% year to date, even after the company reported a world-record quantum error-correction result with its Helios system reaching 99.9995% logical fidelity.

Any move toward the target would likely hinge less on near-term revenue and more on the market re-rating a business whose roadmap runs from Helios to Sol (planned for 2027) and Apollo (2029). Trailing revenue stands at only about $23 million against a market capitalization near $8.9 billion, so the valuation rests almost entirely on expectations for future commercial adoption rather than current profitability. From what I see, this dynamic makes the name particularly sensitive to both milestone delivery and broader risk sentiment.

Elements That Could Support Higher Prices

• A $2.11 billion cash balance against just $32.7 million in debt supplies a lengthy runway for research and commercialization efforts.
• The Helios error-correction milestone, along with announced system sales such as the Oracle deal and a memorandum of understanding with Saudi Aramco, provides early commercial validation.
• Morgan Stanley’s upgrade to Overweight and top-pick designation underscores leadership in error-correction technology.
• Inclusion in Russell indexes may draw passive and index-related buying interest.

Obstacles That Could Limit Upside

• Losses remain substantial, with trailing loss per share of roughly $4.72 and negative operating cash flow, and profitability is not expected in the near term.
• A price-to-sales ratio above 300 times and a price-to-book multiple near 3 times leave scant margin for any shortfall.
• Delays in the Sol or Apollo timelines would weaken the premium-valuation case.
• Competition in quantum hardware continues to intensify, and sentiment toward speculative technology stocks can shift rapidly when rates rise or risk appetite declines.

Technical Context and Market Structure

As a recent IPO, long-term technical history remains limited. The 50-day moving average sits near $45.50 and currently serves as overhead resistance, with the price trading well below it. An RSI reading in the mid-30s indicates the stock is approaching oversold conditions, though a low RSI by itself does not define support. Short interest around 18% of the float introduces the possibility of a squeeze if positive developments prompt covering. The psychological $40 level and the $45 area represent initial hurdles on any recovery path. I’m watching this closely as momentum indicators evolve.

Time Horizon and Items to Monitor

Analyst targets generally assume a 12-month horizon, yet the wide $60-to-$155 dispersion shows differing assumptions about visibility. The next confirmed earnings report is set for November 5, 2026. Investors should track revenue trends, loss-per-share developments, any updates to the Sol and Apollo timelines, additional commercial system sales or partnerships, and broader interest-rate and risk-appetite conditions that influence multiples for speculative growth companies.

Using AI Tools in My Research

In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a data-driven perspective on volatile names like this. The tool monitors thousands of securities and provides signals that can complement fundamental analysis. It has helped me spot shifts in momentum more efficiently when reviewing opportunities in emerging technology sectors.

Final Assessment

The $95 central target—the average of 11 published analyst targets spanning $60 to $155—implies a roughly 183% move from a recent $33.60 close. That sizable gap reflects both the technology’s potential and the market’s current skepticism. Support stems from a strong cash position, record error-correction results, and a clear hardware roadmap, while the challenges are considerable: ongoing losses, an extreme sales multiple, and execution risk on multi-year timelines. The wide analyst dispersion indicates that reaching $95 is plausible only if Quantinuum’s commercial milestones translate into real revenue growth. Investors should monitor earnings, roadmap execution, and market risk appetite before drawing conclusions, and no outcome here is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume